Ziff Brothers Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ziff Brothers Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$14.9M	Sell	219,602 -113,964	-34%	-$8.04M	5.58%	10
2016 Q2	$18.5M	Buy	333,566 +165,000	+98%	+$10.4M	4.61%	10
2016 Q1	$10.6M	Buy	168,566 +106,268	+171%	+$7.07M	2.48%	10
2015 Q4	$5.87M	Buy	62,298 +37,298	+149%	+$3.46M	1.63%	13
2015 Q3	$2.01M	Buy	+25,000	New	+$2.78M	0.71%	15

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Ziff Brothers Investments's ALNY Position: Q3 2016 in Review

Ziff Brothers Investments reduced its Alnylam Pharmaceuticals (ALNY) stake by 34% in Q3 2016, selling an estimated $8.04M and leaving 219,602 shares worth $14.9M. The position accounts for 5.58% of the portfolio, ranked #10.

Ziff Brothers Investments first reported a position in ALNY in Q3 2015 and has held it in 5 quarters since. The position peaked at $18.5M in Q2 2016. 259 funds tracked by Wall St. Rank hold ALNY as of Q3 2016.

Ziff Brothers Investments held 219,602 shares of Alnylam Pharmaceuticals worth $14.9M as of Q3 2016.
Ziff Brothers Investments sold 113,964 Alnylam Pharmaceuticals shares in Q3 2016, an estimated $8.04M.
Alnylam Pharmaceuticals made up 5.58% of Ziff Brothers Investments's portfolio in Q3 2016, its #10 holding.
Ziff Brothers Investments first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 5 quarters since.
Ziff Brothers Investments's Alnylam Pharmaceuticals position peaked at $18.5M in Q2 2016.
259 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2016.

Based on Ziff Brothers Investments's 13F filing for Q3 2016, filed 14 Nov 2016.